Type 2 diabetes drug pipeline

Every disclosed next-gen T2D asset by sponsor and phase, plus the M&A and partnerships that built the field.

As of 2026-06-22. Updated as catalysts move.

Pipelines #

Disclosed type-2 diabetes assets by sponsor and phase. Lilly does not disclose Phase 1 publicly.

Sponsor	Filed	Phase 3	Phase 2	Phase 1
Eli LillyLLY	-	Orforgliprontype 2 diabetes Retatrutidetype 2 diabetes Efsitora alfatype 2 diabetes	Bimagrumab + tirzepatidetype 2 diabetes, obesity	-
Novo NordiskNOVO-B.CO	-	CagriSematype 2 diabetes Oral semaglutide 25 mgtype 2 diabetes	Zenagamtide (amycretin)type 2 diabetes, obesity	-
Boehringer Ingelheim	-	-	Survodutidetype 2 diabetes	-
AstraZenecaAZN.L	-	-	AZD5004 (ecnoglutide-class oral GLP-1)type 2 diabetes, obesity	-

Sector M&A and partnerships #

Deals that built the current next-gen diabetes field. Most recent first.

2025-03

Novo Nordisk → United Laboratories

$2.0B+ (ex-Greater China)

Asset: UBT251 (GLP-1/GIP/glucagon triple)

Licensed the triple agonist for obesity, T2D and related indications outside Greater China.

2023-12

Roche → Carmot Therapeutics

$2.7B upfront

Asset: CT-388 (enicepatide), CT-996 oral

GLP-1/GIP and oral GLP-1 incretins spanning obesity and T2D; up to $1.1B in milestones.

2023-11

AstraZeneca → Eccogene

$0.185B upfront

Asset: Elecoglipron (ECC5004 / AZD5004)

Licensed the oral small-molecule GLP-1; up to ~$1.8B in milestones. Now in Phase 2b T2D (SOLSTICE).

2023-06

Eli Lilly → Sigilon Therapeutics

$~0.3B

Asset: Encapsulated cell therapy (type 1 diabetes)

Adds an encapsulated islet-cell platform aimed at insulin independence.

2011

Boehringer Ingelheim → Eli Lilly

Asset: Jardiance, Trajenta

Diabetes Alliance: co-development and co-promotion of the SGLT2 (empagliflozin) and DPP-4 (linagliptin) franchises. Lilly books a share of Jardiance globally.